US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Issue of Equity

5 February 2024 Apollon Formularies Plc (“Apollon” or the “Company”) Issue of Equity Apollon Formularies plc (AQSE: APOL), a UK based international pharmaceutical company trading on the Aquis Growth Market Stock Exchange, is pleased to announce that the Company has issued 18,000,000 Ordinary Shares in, in lieu of cash, in settlement of fees at a deemed price of £0.001 per share for a total value of £18,000. Application will be made for the new Ordinary Shares to be admitted to trading on the Aquis Growth Market and admission to trading is expected in the new Ordinary Shares

Resignation of Non-Executive Director

Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on AQSE Growth Market, announces the resignation of Nicholas (Nick) Ingrassia as a Non-Executive Director with immediate effect to focus on his other business commitments.Nick has sat on the Board of Apollon since it went public on the Aquis Growth market in April 2021. Nick Ingrassia,  of Apollon Formularies, commented “It has been an honour and a pleasure to serve on the Apollon board alongside a group of such brilliant and dedicated directors. I

Update on Global Hemp Group

02 August 2023 Apollon Formularies Plc   Update on Global Hemp Group   Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the AQSE Growth Market, that is licenced to research, develop, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision, announces that the Company will not be proceeding with proposed deal with Global Hemp Group Inc. (“GHG”) under  the binding letter of intent (“LOI”) released on the 12th of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe